[Form 4] Immuneering Corporation Insider Trading Activity

Rhea-AI Filing Summary

Immuneering Corporation (IMRX) – Form 4 insider transaction

Director Diana F. Hausman disclosed two open-market purchases executed on 07/02/2025:

• 2,500 Class A common shares acquired directly at $3.5956 per share.
• 3,000 Class A common shares acquired indirectly through a spouse at $3.6245 per share.

Post-transaction beneficial ownership stands at 2,500 shares held directly and 3,000 shares held indirectly, for a combined total of 5,500 shares. No derivative securities were involved and no shares were sold. The filing was signed on 07/07/2025.

Positive

• Director bought 5,500 shares on the open market, showing incremental insider confidence.

Negative

• Purchase size is small relative to Immuneering’s total share count, implying limited market impact.

Insights

Securities Analyst

TL;DR – Small open-market insider buy; positive sentiment signal but immaterial to overall float or valuation.

Director purchases generally indicate insider confidence. Hausman’s acquisition of 5,500 shares at an average price of roughly $3.61 suggests personal conviction in Immuneering’s prospects. However, the dollar value is modest and represents a negligible percentage of outstanding shares, limiting its fundamental impact. No sales or derivative hedges accompany the trade, so the transaction is a straightforward long equity position. For investors, the filing is a mild positive sentiment cue rather than a catalyst likely to affect valuation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HAUSMAN DIANA

(Last) (First) (Middle)

245 MAIN STREET

2ND FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/02/2025		P		2,500	A	$3.5956	2,500	D
Class A Common Stock	07/02/2025		P		3,000	A	$3.6245	3,000	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Diana F. Hausman	07/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many IMRX shares did Director Diana Hausman purchase?

She bought 5,500 Class A common shares on 07/02/2025.

What prices were paid for the IMRX shares?

Shares were purchased at $3.5956 and $3.6245 per share.

What is Diana Hausman’s total IMRX ownership after the transaction?

She now beneficially owns 5,500 shares (2,500 directly and 3,000 indirectly via spouse).

Were any IMRX shares sold in this Form 4 filing?

No. The filing reports only purchases; there were no sales.

Did the filing include any derivative securities?

No derivative securities were reported in Table II.